Streetbeat News

Analyst Ratings

DDOG

Rosenblatt analyst Blair Abernethy maintains a 'Buy' rating on Datadog (NASDAQ:DDOG) and raises the price target from $100 to $110.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 11:09 am

FIVN

Needham analyst Scott Berg has reiterated a 'Buy' rating on Five9 (NASDAQ:FIVN) and maintained a price target of $90.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 11:08 am

FUSN

Fusion Pharmaceuticals (NASDAQ:FUSN) reported Q2 losses of $(0.38) per share, beating the analyst consensus estimate of $(0.39) by 2.56 percent. However, the company's quarterly sales of $34.00 thousand missed the analyst consensus estimate of $80.00 thousand by 57.50 percent, marking a 94.04 percent decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:07 am

PTRA

BTIG analyst Greg Lewis has downgraded Proterra (NASDAQ:PTRA) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 11:06 am

SAGE

Canaccord Genuity analyst Sumant Kulkarni has downgraded Sage Therapeutics from Buy to Hold and lowered the price target from $64 to $21.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 11:05 am

TWKS

Thoughtworks Holding (NASDAQ:TWKS) reported Q2 earnings of $0.03 per share, missing the analyst consensus estimate of $0.04 by 25%. This is a 72.73% decrease from the same period last year. The company also reported quarterly sales of $287.21 million, missing the analyst consensus estimate of $301.50 million by 4.74%. This is a 13.52% decrease from the same period last year.

Portfolio Pulse from saritha@benzinga.com

August 08, 2023 | 11:05 am

SOHU

Citigroup analyst Alicia Yap has maintained a 'Buy' rating on Sohu.com (NASDAQ:SOHU) but lowered the price target from $21 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:05 am

CIFR

Cipher Mining (NASDAQ:CIFR) reported Q2 earnings of $0.04 per share, beating the analyst consensus estimate of $(0.03) by 233.33%. This is a 150% increase over losses of $(0.08) per share from the same period last year. However, the company's quarterly sales of $31.22 million missed the analyst consensus estimate of $32.20 million by 3.04%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:03 am

ABOS

Acumen Pharmaceuticals reported Q2 losses of $(0.28) per share, beating the analyst consensus estimate of $(0.36) by 22.22 percent. However, this is a 12 percent increase in losses compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

August 08, 2023 | 11:02 am

FLR

Citigroup analyst Andrew Kaplowitz maintains a Neutral rating on Fluor (NYSE:FLR) and raises the price target from $32 to $40.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:02 am